TransMedics Group Inc. (TMDX)
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
TransMedics: Continued Strength Suggests Further Upside
TransMedics delivered strong Q2 results, with revenue growth remaining robust and margins improving sharply. While there are concerns around the regulatory environment, competition, and seasonality, TransMedics' next-gen heart and lung programs are near-term growth catalysts. I see further upside, but meaningful gains may not materialize until 2026, when the heart and lung opportunity becomes more clear.
TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Dorothy Morgan - Gilmartin Group LLC K. Gong - JPMorgan Chase & Co, Research Division Christian Pasquale - Nephron Research Joshua Jennings - TD Cowen, Research Division Samantha Munoz - Piper Sandler & Co., Research Division Zachary Day - Canaccord Genuity Xuesong Wang - Morgan Stanley Suraj Kalia - Oppenheimer & Co. Inc., Research Division David Rescott - Robert W.
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.35 per share a year ago.
Live Earnings: Will TransMedics (TMDX) Rally After Earnings?
TransMedics Group reports its Q2 earnings after the bell. Wall Street current expectations stand at: Revenue: $147.74 million Adjusted EPS: $.43 We'll be updating this live blog with updates during the trading day and then once earnings hit the newswires will post a flurry of news and analysis.
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
Beyond analysts' top-and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Why TransMedics Remains A Buy Into 2026
TransMedics beat Q1 2025 estimates and raised full-year guidance, showing strong revenue and earnings growth. The company holds a unique market position with the only FDA-approved system for heart, lung, and liver transport. Profitability and margins are improving, though free cash flow, dilution, and a limited TAM remain concerns.
TransMedics: Q2 Analyst Estimates Will Fall Short
TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings beat, with flight activity data suggesting sales could surpass analyst estimates. The company is showing clear operating leverage, manageable debt, and is building a vertically integrated logistics network in a niche market.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy
TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beats can sustain premium multiples as it scales.
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
TransMedics Group, Inc. (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
